ClinicalTrials.gov record
Completed Not applicable Interventional Results available

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

ClinicalTrials.gov ID: NCT00421304

Public ClinicalTrials.gov record NCT00421304. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 4, 2026, 4:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), for the Treatment of Children Hospitalized With RSV Illness

Study identification

NCT ID
NCT00421304
Recruitment status
Completed
Study type
Interventional
Phase
Not applicable
Lead sponsor
MedImmune LLC
Industry
Enrollment
118 participants

Conditions and interventions

Interventions

  • Motavizumab Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
0 Months to 12 Months
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 9, 2007
Primary completion
Sep 16, 2009
Completion
Sep 16, 2009
Last update posted
Aug 26, 2021

2007 – 2009

United States locations

U.S. sites
26
U.S. states
17
U.S. cities
26
Facility City State ZIP Site status
Research Site Tucson Arizona 85724
Research Site Long Beach California 90806
Research Site Orange California 92868
Research Site San Diego California 92123
Research Site Jacksonville Florida
Research Site Honolulu Hawaii 96826
Research Site Chicago Illinois 60612
Research Site Oak Lawn Illinois 60453
Research Site Boston Massachusetts 02111
Research Site Jackson Mississippi 39216-4505
Research Site Omaha Nebraska 68198
Research Site Brooklyn New York 11201
Research Site Buffalo New York 14222
Research Site Mineola New York 11501
Research Site New Hyde Park New York 11040
Research Site Rochester New York 14642
Research Site Syracuse New York 13210
Research Site Columbus Ohio 43205
Research Site Oklahoma City Oklahoma 73104-5066
Research Site Portland Oregon 97239
Research Site Dallas Texas 75390
Research Site Houston Texas 77030
Research Site Salt Lake City Utah 84108
Research Site Seattle Washington 98105
Research Site Morgantown West Virginia 26506
Research Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00421304, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 26, 2021 · Synced May 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00421304 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →